EXELIXIS, INC. (EXEL)
A
Pipeline Grade
Financial Position (from SEC Filings)
$226.2M
Cash & Equivalents
$251.8M
Quarterly Burn Rate
$12,575M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CABOZANTINIB S-MALATE
COMETRIQ |
APPROVED | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Adipocytic Sarcoma, Advanced Adult Hepatocellular Carcinoma, Advanced Cancer, Various, NOS, Advanced Leiomyosarcoma, Advanced Liposarcoma, Advanced Metastatic Melanoma, Advanced NSCLC, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Advanced/Metastatic, Anaplastic Thyroid Cancer, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS), Bile Duct Cancer, Bladder Cancer, Bone Metastases of a Malignant Tumor, Bone, Metastatic Cancer, BRAF Mutation-Related Tumors, Brain Metastases, Breast Cancer, Cancer, Carcinoid Tumor, Carcinoma, Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Castration-resistant Prostate Cancer, Cervical Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Chromophobe Renal Cell Carcinoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, Clear Cell Renal Cancer, Clear Cell Renal Carcinoma, Clear Cell Renal Cel |
Upcoming Catalysts
No upcoming catalysts detected for this company.